logo/base Created with Sketch.
See product brochures

FibroScan® Mini+ 430

The mobile non-invasive solution for liver disease management.

Powered by LSM by VCTE® and CAP for liver fibrosis and liver steatosis assessment.

chevron chevron

Seamlessly adaptable to all settings

FibroScan® Mini+ 430 is designed for multi-center sharing and remote liver patient management.

Mobile

Light and easy to handle with airplane-compatible transport suitcase. Battery-powered device

Innovative Design

Winner of the Red Dot Design Award 2017

All Patient Morphologies

Can be used with all probes S+, M+ and XL+

Renowned & Endorsed

Supported by 6,270+ peer reviewed publications and 250+ international guidelines

Patented and Validated

LSM by VCTE® is unique, patented and validated for liver fibrosis assessment. It is the standard for non-invasive evaluation of liver stiffness with 5,540+ international peer-reviewed publications.1

CAP is unique patented and validated for liver steatosis assessment2,3 with 2,125+ international peer-reviewed publications.

Learn more
FibroScan® Mini+ 430

Guided VCTE® : The next generation VCTE® technology

The new Guided VCTE® technology offers intuitive features for faster examinations and simplified scanning.

Learn more about Guided VCTE More information about FibroScan exams

FibroScan® Mini+ 430 comes with a dedicated support

From installation, to training and local support, we provide you with the highest quality of services.

Learn more

Extend FibroScan® use

Beyond FibroScan®, Echosens develops solutions to optimize the management of liver diseases and assist in guiding treatment decisions.

  • FibroScan® Guided VCTE

    Guided VCTE®

    Seamless liver health assessment for all

    chevron
  • FibroScan® probes

    VCTE® probe

    Optimize measurement accuracy on all patient morphologies

    chevron
  • Liver Health Management

    Liver Health Management

    Cloud-based solution to assist clinicians in providing comprehensive liver care.

    chevron
  • FibroScan® Gateway

    FibroScan® Gateway

    Optimize clinical workflows with real-time secure data transmission

    chevron

What our users say

Assessment of liver stiffness and fat by non-invasive method is a huge step forward towards better management of MASLD. It has hugely impacted the way clinicians stratify the patients, chose therapy and monitor response!

Akash Shukla

Professor & Head Department of Gastroenterology Seth GSMC & KEM Hospital Mumbai

In the mobile screening program, the FibroScan is both a screening tool and a diagnostic referral tool. It allows us to open up discussion on alcohol and viral hepatitis issues, but also to screen for hepatopathies and organize appropriate follow-up. This tool gives us great autonomy and supports our Risk Reduction approach.

Johann Volant

HIV-Hepatitis Coordinator Association Gaïa-Paris

Guided VCTE helps improve operator efficiency and perhaps standardize their performance. We expect that Guided VCTE features will improve the reliability of LSM without prolonging the study duration, even in patients with MASLD.

Dr. Raj Vuppalanchi

Professor of Medicine, Director of Hepatology and Associate Program Director | Indiana University School of Medicine

Read all testimonials chevron

Request a demo!

Interested in FibroScan®?

Contact us

1. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.

2. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022.

3. Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool or the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911.doi:10.1097/MEG.0b013e32835f4c3d.

FibroScan® Mini+ 430 or FibroScan® Mini 430: product name may differ depending on country.

FibroScan® 430 Mini/Mini+ is a class IIa medical device according to Rule 10 of ANNEX VIII of Regulation EU 2017/745 (CE 0459) and is manufactured by Echosens™. FibroScan® 430 Mini/Mini+ is intended to provide Liver stiffness measurements at a shear wave frequency of 50 Hz and Liver ultrasound attenuation measurements (CAP: Controlled Attenuation Parameter) at 3.5 MHz. FibroScan® 430 Mini/Mini+ is a non-invasive device intended to aid clinical management, diagnosis, and monitoring of patients with confirmed or suspected chronic liver disease, as part of an overall assessment of the liver. FibroScan® device may aid the healthcare professionals in the assessment of liver fibrosis, steatosis, and in determining the likelihood of cirrhosis. FibroScan® device is used, in conjunction with other clinical and laboratory data, during liver assessment in patients with confirmed or suspected chronic liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.
chevron User Guides FibroScan Mini+ 430